Bionyra Pharma Announces First Healthy Volunteers Dosed in Phase 1 Study of BYN-001, a Long-Acting IL-25 Antibody for Atopic Dermatitis
Bionyra Pharma, a clinical-stage biopharmaceutical company developing next-generation biologics designed to unlock the potential of multi-targeted biology in immune-mediated inflammatory diseases, today announced that the first healthy volunteers have been dosed in the Phase 1 study of BYN-001, the company's long-acting anti-IL-25 monoclonal antibody being developed for atopic dermatitis.
Bionyra Pharma Launches with $165 million Oversubscribed Series A to Advance Clinical Stage Pipeline of Next Generation Biologics for Immune-Mediated Inflammatory Diseases
Bionyra Pharma, a clinical-stage biopharmaceutical company developing next-generation biologics for immune-mediated inflammatory diseases, today announced the company’s launch and its $165 million (~€143 million) oversubscribed Series A financing co-led by Jeito Capital and Sofinnova Partners. Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners and Apollo Health Ventures also participated in this inaugural funding. The company received seed financing from Sofinnova Partners and was co-founded with former Sanofi R&D executive Dr. Frédéric Marrache, who serves as CEO of the company. Bionyra is advancing next-generation mono and multispecific antibodies for diseases with high unmet need despite currently available treatments, including atopic dermatitis and inflammatory bowel disease (IBD).
